Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H A Austin

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Clinical Nephrology|September 1, 1988
Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancerD E Webb, H A Austin, A Belldegrun, et al.
Medicine|July 1, 1985
Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factorsJ P Johnson, J Moore, H A Austin, et al.
The Journal of Rheumatology|November 1, 1992
Human immunodeficiency virus (HIV) and HIV infected cells in saliva and salivary glands of a patient with systemic lupus erythematosusC K Yeh, P C Fox, Y Goto, et al.
The New England Journal of Medicine|January 5, 1984
Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoidesS D Averbuch, H A Austin, S A Sherwin, et al.
The Journal of Urology|March 1, 1989
Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomyA Belldegrun, D E Webb, H A Austin, et al.
Annals of Internal Medicine|September 1, 1993
Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapyD T Boumpas, H A Austin, E M Vaughan, et al.
The Journal of Rheumatology|February 1, 1996
Outpatient monthly oral bolus cyclophosphamide therapy in systemic lupus erythematosusS M Dawisha, C H Yarboro, E M Vaughan, et al.
Annals of Internal Medicine|July 1, 1995
Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesisD T Boumpas, B J Fessler, H A Austin, et al.
Annals of Internal Medicine|June 15, 1995
Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic diseaseD T Boumpas, H A Austin, B J Fessler, et al.
Gastroenterology|August 1, 1995
Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfaH S Conjeevaram, J H Hoofnagle, H A Austin, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Clinical Nephrology|September 1, 1988
Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancerD E Webb, H A Austin, A Belldegrun, et al.
Medicine|July 1, 1985
Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factorsJ P Johnson, J Moore, H A Austin, et al.
The Journal of Rheumatology|November 1, 1992
Human immunodeficiency virus (HIV) and HIV infected cells in saliva and salivary glands of a patient with systemic lupus erythematosusC K Yeh, P C Fox, Y Goto, et al.
The New England Journal of Medicine|January 5, 1984
Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoidesS D Averbuch, H A Austin, S A Sherwin, et al.
The Journal of Urology|March 1, 1989
Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomyA Belldegrun, D E Webb, H A Austin, et al.
Annals of Internal Medicine|September 1, 1993
Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapyD T Boumpas, H A Austin, E M Vaughan, et al.
The Journal of Rheumatology|February 1, 1996
Outpatient monthly oral bolus cyclophosphamide therapy in systemic lupus erythematosusS M Dawisha, C H Yarboro, E M Vaughan, et al.
Annals of Internal Medicine|July 1, 1995
Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesisD T Boumpas, B J Fessler, H A Austin, et al.
Annals of Internal Medicine|June 15, 1995
Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic diseaseD T Boumpas, H A Austin, B J Fessler, et al.
Gastroenterology|August 1, 1995
Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfaH S Conjeevaram, J H Hoofnagle, H A Austin, et al.
Pageof 7